Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06236802 · ClinicalTrials.gov registry record · NA

ProVIDE II Bridging Study

A NA study of BPH With Symptomatic Lower Urinary Tract Symptoms, sponsored by ProVerum Medical.

Active
Registry status
NA
Development phase
40
Enrollment target
8
Study locations

NCT06236802 is a NA study of BPH With Symptomatic Lower Urinary Tract Symptoms that is active but no longer recruiting, run by ProVerum Medical. The registered enrollment target is 40 participants. The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06236802, a NA study of BPH With Symptomatic Lower Urinary Tract Symptoms, is active but no longer recruiting, sponsored by ProVerum Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
8
Study locations

Study Summary

The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.

Interventions

  • DEVICE ProVee device

Study Locations (8)

Texas

  • Midtown Urology Assoc. PA - Austin
  • Urology Austin - Austin
  • Houston Methodist Research Institute - Houston

Florida

  • Florida Urology Partners, LLP - Tampa
  • Avant Concierge Urology - Winter Garden

Illinois

  • Comprehensive Urologic Care - Lake Barrington

Nevada

  • Sheldon Freeman MD LTD - Las Vegas

Other

  • St James Hospital - Dublin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-03-06
Est. Completion 2029-06-01
Phase NA

Sponsor

ProVerum Medical

2 total trials

What the Registry Record Tells You About NCT06236802

The ClinicalTrials.gov registry entry for NCT06236802 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProVerum Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with BPH With Symptomatic Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 1 intervention - of which ProVee device is the first listed.

NCT06236802 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Texas, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06236802 about?

NCT06236802 is a clinical study titled "ProVIDE II Bridging Study". The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.

What is the current status of trial NCT06236802?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-03-06. Estimated completion is 2029-06-01.

What conditions does trial NCT06236802 study?

This clinical trial studies the following conditions: BPH With Symptomatic Lower Urinary Tract Symptoms.

What interventions are being tested in trial NCT06236802?

The interventions under investigation include: ProVee device (DEVICE).

Who is sponsoring clinical trial NCT06236802?

This trial is sponsored by ProVerum Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06236802 being conducted?

This trial has 8 study locations across Florida, Illinois, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for BPH With Symptomatic Lower Urinary Tract Symptoms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.